Screener
Veradermics MANE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Veradermics’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
FAQ
- What is Veradermics's cash & equivalents?
- Veradermics (MANE) reported cash & equivalents of $168.41M in Q1 2026.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Veradermics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude